These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 16625863)

  • 41. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
    Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
    Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current medical treatment of pancreatic neuroendocrine tumors.
    Yalcin S; Oyan B; Bayraktar Y
    Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of somatostatin and dopamine D2 receptors in endocrine tumors.
    Gatto F; Hofland LJ
    Endocr Relat Cancer; 2011 Dec; 18(6):R233-51. PubMed ID: 22135243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Somatostatin analogs and radiopeptides in cancer therapy.
    Froidevaux S; Eberle AN
    Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
    Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
    Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Somatostatin analogs in oncology].
    Thomas F; Parmar H; Prevost G; Kuhn JM; Bejot JL; Moreau JP; Bogden A
    Bull Cancer; 1991; 78(8):693-707. PubMed ID: 1681967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
    McCarthy KE; Woltering EA; Anthony LB
    Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
    Appetecchia M; Baldelli R
    J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia.
    Panzuto F; Magi L; Rinzivillo M
    Expert Opin Drug Saf; 2021 Apr; 20(4):383-386. PubMed ID: 33530760
    [No Abstract]   [Full Text] [Related]  

  • 53. Update in the Therapy of Advanced Neuroendocrine Tumors.
    Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
    Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update on gastroenteropancreatic neuroendocrine tumors.
    Cives M; Strosberg J
    Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment.
    Reubi JC
    Neuroendocrinology; 2004; 80 Suppl 1():51-6. PubMed ID: 15477718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
    Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
    J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
    [No Abstract]   [Full Text] [Related]  

  • 57. Advances in chemotherapy and biotherapy of endocrine tumors.
    Oberg K
    Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P; Phan AT; Adelman DT; Iwasaki M
    Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
    Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
    Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.